 |
|
|
| Éditorial |
|
De la biologie aux thérapies moléculaires ciblées : le cancer du rein
A Ravaud, C Massard
|
 Article gratuit
|
|
| Synthèse |
|
Signalling pathways in renal-cell carcinoma: from the molecular biology to the futur therapy
J Edeline, C Vigneau, J-J Patard, N Rioux-Leclercq
|
Résumé
Article gratuit
 Summary
|
Renal cell carcinoma management and therapies in 2010
B Albouy, M Gross Goupil, B Escudier, C Massard
|
Résumé
Article gratuit
Summary
|
Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab
E Barrascout, J Medioni, F Scotte, J Ayllon, A Mejean, C A Cuenod, Eric Tartour, R Elaidi, S Oudard
|
Résumé
Article gratuit
Summary
|
mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma
A Ravaud, J-C Bernhard, M Gross-Goupil, L Digue, J-M Ferriere
|
Résumé
Article gratuit
Summary
|
New therapeutics strategies in renal cell carcinoma
J-B Meric, B Billemont, O Rixe
|
Résumé
Article gratuit
Summary
|
Targeted therapies: sequential and combined treatments
M Gross-Goupil, B Escudier
|
Résumé
Article gratuit
Summary
|
Management of side effects associated with antiangiogenic treatment in renal cell carcinoma
A Fléchon, H Boyle, S Négrier
|
Résumé
Article gratuit
Summary
|
Advanced renal carcinomas with special situations. How to treat them?
D Pouessel, J-J Patard, S Culine
|
Résumé
Article gratuit
Summary
|
What is the importance of kidney cancer surgery in contrast with targeted therapies ?
G Ploussard, A de La Taille
|
Résumé
Article gratuit
Summary
|
|
